MQMei-Hong Qiu

Mei-Hong Qiu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mei-Hong Qiu has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Jun Lu

    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

    7 shared publications
  • Zhi-Li Huang

    Department of Pharmacology, School of Basic Medical Sciences, State Key Laboratory of Medical Neurobiology, Institutes of Brain Science and Collaborative Innovation Center for Brain Science, Joint International Research Laboratory of Sleep, Fudan University, Shanghai, China

    5 shared publications
  • Michael C. Chen

    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, 709 CLS, Blackfan Circle #3, Boston, MA, 02115, USA

    3 shared publications
  • Zhi-Gang Zhong

    Department of Neurobiology, Institute for Basic Research on Aging and Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China

    3 shared publications
  • Feng‐Yan Sun

    Department of Neurobiology, Institute for Basic Research on Aging and Medicine, School of Basic Medical Sciences Fudan University Shanghai China

    2 shared publications
  • M.C. Chen

    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA

    2 shared publications

Latest Publications

  • Striatal Dopamine D2 Receptors Contribute to N-Ethylpentylone-Induced Arousal in Mice

    by Cheng-Teng Fan, Jing-Ya Wang, Hong Qian, Shang-Qi Tang, Zhi-Gang Zhong, Yu-Rong Zhang, Shui-Qing Zheng, Mei-Hong Qiu, Yu-Lan Rao, Zhi-Ru Xu

  • Open Access

    Early-life sleep disruption in Shank3-deficient rats: A preclinical model for autism-related sleep mechanisms and interventions

    by Mei-Hong Qiu, Zhi-Gang Zhong, Pei-Wen Song, Gui-Jin Tao, Jin-Tao Zhang, Yong-Hua Chen, Tian-Jia Song, Wei-Min Qu, Rong Zhang, Zhi-Li Huang

    Sleep disturbances are among the most prevalent and early-emerging features of autism spectrum disorder (ASD), often preceding core behavioral symptoms. Despite their clinical relevance, the neurobiological mechanisms driving early-life sleep disruption in ASD remain poorly understood. Shank3 , encoding a synaptic scaffolding protein at excitatory synapses, is one of the most well-established monogenic risk factors for ASD. Here, we systematically investigated sleep architecture and homeostatic regulation in juvenile Shank3 Δe11–21 rats, which lack Shank3 protein and display ASD-like behavioral and sensory phenotypes. EEG/EMG recordings revealed sex-specific abnormalities: males exhibited fragmented sleep with frequent brief arousals, whereas females showed prolonged wakefulness. Both sexes demonstrated reduced NREM sleep δ power, indicating diminished sleep depth. Following 6-h sleep deprivation, Shank3 −/− rats displayed blunted homeostatic rebound. Additionally, Clock and Bmal1 mRNA were significantly downregulated in prefrontal cortex and striatum, implicating circadian dysregulation within corticostriatal circuits. Collectively, these findings indicate that Shank3 deficiency leads to early-onset, low-quality sleep accompanied by impaired homeostatic and circadian regulation. This phenotype mirrors clinical sleep disturbances in children with ASD, supporting sleep dysfunction as an intrinsic, early feature of Shank3 -related pathophysiology. Together with prior behavioral evidence, this study establishes the Shank3 Δe11–21 rat as a preclinical model for elucidating mechanisms of Shank3 -related neurodevelopmental disorders and for evaluating potential early-life therapeutic interventions, including sleep-targeted strategies.


  • Open Access

    小鼠背外侧被盖下核γ-氨基丁酸能神经元的全脑单突触输入

    by Zhong Zhi-Gang, Tang Shang-Qi, Ben Hui, Yang Jia-Lin, Chen Yong-Hua, Qu Wei-Min, Huang Zhi-Li, Qiu Mei-Hong

    The sublaterodorsal tegmental nucleus (SLD) is a critical hub for regulating REM sleep and muscle atonia, with its dysfunction linked to disorders such as REM sleep behavior disorder (RBD) and cataplexy. However, the presynaptic patterns influencing SLD GABAergic neurons-one of the primary neuronal subtypes within the SLD-remain poorly understood. Here, we employed a modified rabies virus in conjunction with a Cre/loxP gene-expression strategy to systematically map and quantify the whole-brain monosynaptic afferents to SLD GABAergic neurons in mice. We identified 139 distinct brain nuclei targeting these neurons, with the majority of inputs originating from the midbrain, pons, and medulla, and 67.99% of the input neurons originating ipsilaterally and 32.01% contralaterally. Notably, the mesencephalic reticular nucleus, superior colliculus, oral part of the pontine reticular nucleus, gigantocellular reticular nucleus, lateral hypothalamic area, and zona incerta were found to be the primary sources of input to SLD GABAergic neurons. Additionally, certain input nuclei displayed a contralateral dominance in their projections to SLD GABAergic neurons. Immunofluorescence staining further revealed that input neurons expressed a variety of neuronal markers associated with important physiological behaviors. These findings provide a relatively comprehensive anatomical insights into the integration of diverse information by SLD GABAergic neurons, shedding light on their roles in regulating complex physiological functions, and offer new avenues for exploring their functional contributions to sleep and motor control.


  • Open Access

    Alleviating sleep disturbances and modulating neuronal activity after ischemia: Evidence for the benefits of zolpidem in stroke recovery

    by Zhi‐Gang Zhong, Gui‐Jin Tao, Shu‐Mei Hao, Hui Ben, Wei‐Min Qu, Feng‐Yan Sun, Zhi‐Li Huang, Mei‐Hong Qiu

    Aims: Sleep disorders are prevalent among stroke survivors and impede stroke recovery, yet they are still insufficiently considered in the management of stroke patients, and the mechanisms by which they occur remain unclear. There is evidence that boosting phasic GABA signaling with zolpidem during the repair phase improves stroke recovery by enhancing neural plasticity; however, as a non‐benzodiazepine hypnotic, the effects of zolpidem on post‐stroke sleep disorders remain unclear. Method: Transient ischemic stroke in male rats was induced with a 30‐minute middle cerebral artery occlusion. Zolpidem or vehicle was intraperitoneally delivered once daily from 2 to 7 days after the stroke, and the electroencephalogram and electromyogram were recorded simultaneously. At 24 h after ischemia, c‐Fos immunostaining was used to assess the effect of transient ischemic stroke and acute zolpidem treatment on neuronal activity. Results: In addition to the effects on reducing brain damage and mitigating behavioral deficits, repeated zolpidem treatment during the subacute phase of stroke quickly ameliorated circadian rhythm disruption, alleviated sleep fragmentation, and increased sleep depth in ischemic rats. Immunohistochemical staining showed that in contrast to robust activation in para‐infarct and some remote areas by 24 h after the onset of focal ischemia, the activity of the ipsilateral suprachiasmatic nucleus, the biological rhythm center, was strongly suppressed. A single dose of zolpidem significantly upregulated c‐Fos expression in the ipsilateral suprachiasmatic nucleus to levels comparable to the contralateral side. Conclusion: Stroke leads to suprachiasmatic nucleus dysfunction. Zolpidem restores suprachiasmatic nucleus activity and effectively alleviates post‐stroke sleep disturbances, indicating its potential to promote stroke recovery.


  • Open Access

    Melatonin supplementation in the subacute phase after ischemia alleviates postischemic sleep disturbances in rats

    by Shu‐Mei Hao, Zhi‐Gang Zhong, Wei‐Min Qu, Zhi‐Li Huang, Feng‐Yan Sun, Mei‐Hong Qiu

    Background: Sleep disorders are highly prevalent among stroke survivors and impede stroke recovery. It is well established that melatonin has neuroprotective effects in animal models of ischemic stroke. However, as a modulator of endogenous physiological circadian rhythms, the effects of melatonin on poststroke sleep disorders remain unclear. In the present study, we investigated how melatonin delivered intraperitoneally once daily in the subacute phase after stroke onset, influencing neuronal survival, motor recovery, and sleep–wake profiles in rats.Methods: Transient ischemic stroke in male Sprague–Dawley rats was induced with 30 min occlusion of the middle cerebral artery. Melatonin or vehicle was delivered intraperitoneally once daily in the subacute phase, from 2 to 7 days after stroke. Electroencephalogram and electromyogram recordings were obtained simultaneously.Results: Compared to the effects observed in the vehicle‐treated ischemic group, after 6 daily consecutive treatment of melatonin at 10 mg/kg starting at ischemic/reperfusion day 2, the infarct volume was significantly decreased (from 39.6 to 26.2%), and the degeneration of axons in the ipsilateral striatum and the contralateral corpus callosum were significantly alleviated. Sensorimotor performances were obviously improved as evidenced by significant increases in the latency to falling off the wire and in the use of the impaired forelimb. In addition to those predictable results of reducing brain tissue damage and mitigating behavioral deficits, repeated melatonin treatment during the subacute phase of stroke also alleviated sleep fragmentation through reducing sleep‐wake stage transitions and stage bouts, together with increasing stage durations. Furthermore, daily administration of melatonin at 9 a.m. significantly increased the nonrapid eye movement sleep delta power during both the light and dark periods and decreased the degree of reduction of the circadian index.Conclusions: Melatonin promptly reversed ischemia‐induced sleep disturbances. The neuroprotective effects of melatonin on ischemic injury may be partially associated with its role in sleep modulation.


  • Open Access

    Noninvasive Ultrasound Stimulation of Ventral Tegmental Area Induces Reanimation from General Anaesthesia in Mice

    by Tianyuan Bian, Wen Meng, Meihong Qiu, Zhigang Zhong, Zhengrong Lin, Junjie Zou, Yibo Wang, Xiaowei Huang, Lisheng Xu, Tifei Yuan, et al.

    Evidence in animals suggests that deep brain stimulation or optogenetics can be used for recovery from disorders of consciousness (DOC). However, these treatments require invasive procedures. This report presents a noninvasive strategy to stimulate central nervous system neurons selectively for recovery from DOC in mice. Through the delivery of ultrasound energy to the ventral tegmental area, mice were aroused from an unconscious, anaesthetized state in this study, and this process was controlled by adjusting the ultrasound parameters. The mice in the sham group under isoflurane-induced, continuous, steady-state general anaesthesia did not regain their righting reflex. On insonation, the emergence time from inhaled isoflurane anaesthesia decreased (sham: 13.63 ± 0.53   min , ultrasound: 1.5 ± 0.19   min , p < 0.001 ). Further, the induction time (sham: 12.0 ± 0.6   min , ultrasound: 17.88 ± 0.64   min , p < 0.001 ) and the concentration for 50% of the maximal effect (EC50) of isoflurane (sham: 0.6%, ultrasound: 0.7%) increased. In addition, ultrasound stimulation reduced the recovery time in mice with traumatic brain injury (sham: 30.38 ± 1.9   min , ultrasound: 7.38 ± 1.02   min , p < 0.01 ). This noninvasive strategy could be used on demand to promote emergence from DOC and may be a potential treatment for such disorders.


  • Nigrostriatal and mesolimbic control of sleep–wake behavior in rat

    by Mei-Hong Qiu, Zhi-Gang Zhong, Michael C. Chen, Jun Lu

    The midbrain dopamine system via the dorsal and ventral striatum regulates a wide range of behaviors. To dissect the role of dopaminergic projections to the dorsal striatum (nigrostriatal projection) and ventral striatum (mesolimbic projection) in sleep–wake behavior, we selectively chemogenetically stimulated nigrostriatal or mesolimbic projections and examined the resulting effects on sleep in rats. Stimulation of nigrostriatal pathways increased sleep and EEG delta power, while stimulation of mesolimbic pathways decreased sleep and reduced cortical EEG power. These results indicate that midbrain dopamine signaling in the dorsal or ventral striatum promotes sleep or wake, respectively.